SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading SAGE News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
13.34%15.5114.2%$283.44m
SHPGShire PLC Sponsored ADR
2.44%174.920.4%$215.65m
PRGOPerrigo Co. Plc
1.79%74.646.4%$145.95m
PRXLPAREXEL International Corporation
-0.16%87.117.9%$127.92m
MNKMallinckrodt Plc
0.04%45.3917.7%$122.33m
ALRAlere Inc.
0.17%50.232.7%$92.00m
JAZZJazz Pharmaceuticals Plc
3.38%159.482.2%$81.35m
ENDPEndo International Plc
2.37%11.658.9%$72.74m
UTHRUnited Therapeutics Corporation
-0.17%131.7013.9%$71.48m
HZNPHorizon Pharma plc
3.85%11.877.6%$57.22m
AERIAerie Pharmaceuticals, Inc.
1.94%55.058.9%$55.22m
ICPTIntercept Pharmaceuticals, Inc.
1.69%130.5722.1%$52.43m
MDCOMedicines Company
-1.75%38.1522.3%$51.45m
ICLRICON Plc
0.25%96.634.2%$37.33m
CTLTCatalent Inc
-0.61%37.792.8%$34.83m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.,0C58C1-E